Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors

Last revised by Daniel J Bell on 15 Apr 2024

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors including palbociclib, ribociclib, and abemaciclib are used in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. Another CDK inhibitor, trilaciclib, has been found to reduce chemotherapy-induced myelosuppression in lung cancer.


CDK4 and CDK6 are downstream protein kinases in the estrogen signaling pathway which control entry into the cell cycle. This inhibition is thought to prevent tumor cell progression in the cell cycle.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.